Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abnormal, abnormally, accurately, acute, adrenal, AEs, affirmative, alanine, aminotransferase, anemia, antitrust, arbitration, arrangement, Art, aspartate, asthenia, attract, benchmarked, bile, bilirubin, billion, Biopharma, bladder, bleed, blood, body, brain, Brendan, carcinoma, cardiac, challenging, clearance, cohort, colon, consent, consummated, consummation, conversely, counsel, count, Court, currency, cytokine, dataset, decision, deep, dehydration, Delaware, denominated, diarrhea, disaggregating, disposing, District, Dr, duct, dysfunction, Eckelman, efficiency, efficiently, encephalopathy, encephalophathy, energy, enrichment, enzyme, expended, expenditure, expert, exposure, extreme, fatigue, febrile, fever, foreign, gallbladder, gastric, gastrointestinal, head, hemorrhagic, hepatobiliary, HNSCC, HSR, hyperbilirubinemia, hypercalcemia, hyponatraemia, inaccurate, INBRX, indirect, inefficient, infarction, infection, inflamed, inflammation, inflammatory, inflation, injury, innovative, instance, instruction, insufficiency, intestine, iv, ix, jaundice, Justice, kidney, lack, lawsuit, led, leverage, lower, lymphatic, malignant, mental, merger, metabolism, mid, misappropriation, muscular, myocardial, nausea, neck, neutropenia, neutropenic, Notably, NSCLC, nutrition, overreactive, overseeing, owe, pancytopenia, Parent, permitted, person, physical, placebo, platelet, pleural, posterior, prioritize, pro, proposal, proposed, prospective, pyrexia, rash, rata, ratio, reaction, reallocate, reclassified, recommendation, reconciliation, recruitment, red, regional, regularly, renal, reorganization, repurchasing, resolve, retire, retrospectively, Sanofi, satisfaction, scrutinize, sensitivity, settle, shareholder, site, small, sodium, spun, sudden, superior, surviving, swelling, syndrome, synovial, tachycardia, technical, thrive, thrombocytopenia, Tracon, transparency, turn, type, unanimously, underfund, underperforming, unjust, unmet, urinary, vi, vii, viii, vision, vomiting, vote, waiting, weather, white, wholly, withdrawn, xi, xii, yield
Removed:
accuracy, acting, activation, advice, agonize, allocating, announcement, antibody, assigned, bio, BioScience, biotechnology, blocking, bluebird, Canada, capable, checkpoint, China, Chinese, clarify, collaborative, combined, conditional, consistent, constrained, creating, dependent, directed, distinct, domain, drew, effort, eligibility, Elpiscience, entitled, excluded, exclusive, failed, fixed, found, fulfill, fulfilled, fusion, government, Holding, Hong, improve, inhibitor, issue, joint, Kong, licensed, lymphoid, Macau, Master, microenvironment, negotiation, nonrefundable, path, point, pool, precise, predominantly, presence, promise, represent, representative, requiring, restructuring, sdAb, selectively, sell, sheet, shown, signaling, standalone, subsequently, symbolic, synergistic, Taiwan, tranche, Transcenta, transfer, typically, venture, worldwide
Financial report summary
?Competition
Amgen • Regeneron Pharmaceuticals • Vertex Pharmaceuticals • Nektar Therapeutics • Sanofi • MacroGenics • GSK • ImmunityBio • Xencor • MorphoSysRisks
- We do not track our research and development expenses on a program-by-program basis, which may impact our ability to efficiently allocate resources and could adversely affect our financial condition and results of operation.
Management Discussion
- License fee revenue during the three months ended March 31, 2023 was $17,000 and consisted of revenue related to our option agreement, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi. We did not recognize any revenue during the three months ended March 31, 2024 following our recognition of all revenue under the Chiesi Option Agreement during the prior year.
- Research and development expenses increased by $26.5 million from $37.4 million during the three months ended March 31, 2023 to $63.9 million during the three months ended March 31, 2024. The overall increase was primarily due to the following factors:
- •contract manufacturing expense increased by $14.9 million, due to the nature of the development and manufacturing activities performed during the current period with our CDMO and CRO partners supporting our clinical and preclinical therapeutic candidates, which reflect the stage-specific needs of our programs and include early and late stage drug substance clinical manufacturing, analytical development, quality control, or QC, testing and stability studies, as well as drug product development, scale-up, robustness studies and selected biologics license applications, or BLA,-enabling activities;